

Philippe Menei

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3733415/publications.pdf>

Version: 2024-02-01

71
papers

4,429
citations

109321

35
h-index

106344

65
g-index

80
all docs

80
docs citations

80
times ranked

5517
citing authors

#	ARTICLE	IF	CITATIONS
1	Transfer Learning from Healthy to Unhealthy Patients for the Automated Classification of Functional Brain Networks in fMRI. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 6925.	2.5	1
2	RNA-sequencing of IDH-wild-type glioblastoma with chromothripsis identifies novel gene fusions with potential oncogenic properties. <i>Translational Oncology</i> , 2021, 14, 100884.	3.7	7
3	What effects does awake craniotomy have on functional and survival outcomes for glioblastoma patients?. <i>Journal of Neuro-Oncology</i> , 2021, 151, 113-121.	2.9	10
4	Immersive Virtual Reality and Ocular Tracking for Brain Mapping During Awake Surgery: Prospective Evaluation Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e24373.	4.3	9
5	A Simple Preoperative Blood Count to Stratify Prognosis in Isocitrate Dehydrogenase-Wildtype Glioblastoma Patients Treated with Radiotherapy plus Concomitant and Adjuvant Temozolomide. <i>Cancers</i> , 2021, 13, 5778.	3.7	10
6	Overt speech critically changes lateralization index and did not allow determination of hemispheric dominance for language: an fMRI study. <i>BMC Neuroscience</i> , 2021, 22, 74.	1.9	1
7	Immersing Patients in a Virtual Reality Environment for Brain Mapping During Awake Surgery: Safety Study. <i>World Neurosurgery</i> , 2020, 134, e937-e943.	1.3	25
8	Mesenchymal Stromal-Like Cells in the Glioma Microenvironment: What Are These Cells?. <i>Cancers</i> , 2020, 12, 2628.	3.7	16
9	The ventral attention network: the mirror of the language network in the right brain hemisphere. <i>Journal of Anatomy</i> , 2020, 237, 632-642.	1.5	21
10	Resting-state functional magnetic resonance imaging versus task-based activity for language mapping and correlation with perioperative cortical mapping. <i>Brain and Behavior</i> , 2019, 9, e01362.	2.2	33
11	<p>Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far</p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 2497-2513.	6.7	15
12	The French glioblastoma biobank (FGB): a national clinicobiological database. <i>Journal of Translational Medicine</i> , 2019, 17, 133.	4.4	19
13	A new glioblastoma cell trap for implantation after surgical resection. <i>Acta Biomaterialia</i> , 2019, 84, 268-279.	8.3	25
14	Whole genome duplication is an early event leading to aneuploidy in IDH-wild type glioblastoma. <i>Oncotarget</i> , 2018, 9, 36017-36028.	1.8	15
15	Integration of transcriptome and proteome profiles in glioblastoma: looking for the missing link. <i>BMC Molecular Biology</i> , 2018, 19, 13.	3.0	24
16	Right Hemisphere Cognitive Functions: From Clinical and Anatomical Bases to Brain Mapping During Awake Craniotomy. Part II: Neuropsychological Tasks and Brain Mapping. <i>World Neurosurgery</i> , 2018, 118, 360-367.	1.3	19
17	Right Hemisphere Cognitive Functions: From Clinical and Anatomic Bases to Brain Mapping During Awake Craniotomy Part I: Clinical and Functional Anatomy. <i>World Neurosurgery</i> , 2018, 118, 348-359.	1.3	26
18	Using a Virtual Reality Social Network During Awake Craniotomy to Map Social Cognition: Prospective Trial. <i>Journal of Medical Internet Research</i> , 2018, 20, e10332.	4.3	24

#	ARTICLE	IF	CITATIONS
19	Intraoperative Subcortical Electrical Mapping of the Optic Tract in Awake Surgery Using a Virtual Reality Headset. <i>World Neurosurgery</i> , 2017, 97, 424-430.	1.3	33
20	Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 135.	8.6	26
21	Response to "Glioma resection and tumor recurrence: back to Semmelweis". <i>Neuro-Oncology</i> , 2016, 18, 1689-1689.	1.2	0
22	Targeting and treatment of glioblastomas with human mesenchymal stem cells carrying ferrociphenol lipid nanocapsules. <i>International Journal of Nanomedicine</i> , 2015, 10, 1259.	6.7	21
23	Characterizing the peritumoral brain zone in glioblastoma: a multidisciplinary analysis. <i>Journal of Neuro-Oncology</i> , 2015, 122, 53-61.	2.9	61
24	Identification of two glioblastoma-associated stromal cell subtypes with different carcinogenic properties in histologically normal surgical margins. <i>Journal of Neuro-Oncology</i> , 2015, 122, 1-10.	2.9	21
25	Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort. <i>Neuro-Oncology</i> , 2015, 17, 1609-1619.	1.2	60
26	Specificities of Awake Craniotomy and Brain Mapping in Children for Resection of Supratentorial Tumors in the Language Area. <i>World Neurosurgery</i> , 2015, 84, 1645-1652.	1.3	48
27	Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone. <i>Neuro-Oncology</i> , 2015, 17, 1322-1332.	1.2	217
28	From the core to beyond the margin: a genomic picture of glioblastoma intratumor heterogeneity. <i>Oncotarget</i> , 2015, 6, 12094-12109.	1.8	75
29	Glioblastoma-associated stromal cells (GASCs) from histologically normal surgical margins have a myofibroblast phenotype and angiogenic properties. <i>Journal of Pathology</i> , 2014, 233, 74-88.	4.5	67
30	French Research Infrastructures to Develop and Validate Glioma Biomarkers. <i>Neurosurgery</i> , 2014, 75, E195-E196.	1.1	2
31	Implanted Carmustine Wafers Followed by Concomitant Radiochemotherapy to Treat Newly Diagnosed Malignant Gliomas: Prospective, Observational, Multicenter Study on 92 Cases. <i>Annals of Surgical Oncology</i> , 2013, 20, 2065-2072.	1.5	38
32	Proteomic analysis of glioblastomas: What is the best brain control sample?. <i>Journal of Proteomics</i> , 2013, 85, 165-173.	2.4	26
33	In vitro and in vivo interactions between glioma and marrow-isolated adult multilineage inducible (MIAMI) cells. <i>Brain Research</i> , 2012, 1473, 193-203.	2.2	10
34	Mesenchymal Stem Cells: Role for Delivering Nanoparticles to Brain Tumors. , 2012, , 251-256.		1
35	Quantitative proteomic Isotope-Coded Protein Label (ICPL) analysis reveals alteration of several functional processes in the glioblastoma. <i>Journal of Proteomics</i> , 2012, 75, 3898-3913.	2.4	37
36	O ⁶ -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide. <i>Cancer</i> , 2012, 118, 4545-4554.	4.1	79

#	ARTICLE	IF	CITATIONS
37	Ferrociphenol lipid nanocapsule delivery by mesenchymal stromal cells in brain tumor therapy. <i>International Journal of Pharmaceutics</i> , 2012, 423, 63-68.	5.2	48
38	Isolation of a new cell population in the glioblastoma microenvironment. <i>Journal of Neuro-Oncology</i> , 2012, 106, 493-504.	2.9	61
39	Tumor eradication in rat glioma and bypass of immunosuppressive barriers using internal radiation with ¹⁸⁸ Re-lipid nanocapsules. <i>Biomaterials</i> , 2011, 32, 6781-6790.	11.4	63
40	The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy. <i>Biomaterials</i> , 2011, 32, 2106-2116.	11.4	69
41	A 4-Gene Signature Associated with Clinical Outcome in High-Grade Gliomas. <i>Clinical Cancer Research</i> , 2011, 17, 317-327.	7.0	73
42	Biodegradable Carmustine Wafers (Gliadel) Alone or in Combination with Chemoradiotherapy: The French Experience. <i>Annals of Surgical Oncology</i> , 2010, 17, 1740-1746.	1.5	69
43	Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. <i>Biomaterials</i> , 2010, 31, 8393-8401.	11.4	208
44	In vivo evaluation of intracellular drug-nanocarriers infused into intracranial tumours by convection-enhanced delivery: distribution and radiosensitisation efficacy. <i>Journal of Neuro-Oncology</i> , 2010, 97, 195-205.	2.9	43
45	DNA methylation in glioblastoma: impact on gene expression and clinical outcome. <i>BMC Genomics</i> , 2010, 11, 701.	2.8	181
46	Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. <i>Neuro-Oncology</i> , 2010, 12, 725-735.	1.2	149
47	Human glioma cell culture: two FCS-free media could be recommended for clinical use in immunotherapy. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2009, 45, 500-511.	1.5	14
48	Neurotrophin-directed differentiation of human adult marrow stromal cells to dopaminergic-like neurons. <i>Bone</i> , 2007, 40, 360-373.	2.9	89
49	Effect of GDNF-releasing biodegradable microspheres on the function and the survival of intrastriatal fetal ventral mesencephalic cell grafts. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2006, 63, 221-228.	4.3	18
50	The brain tissue response to biodegradable poly(methylidene malonate 2.1.2)-based microspheres in the rat. <i>Biomaterials</i> , 2006, 27, 4963-4974.	11.4	21
51	Evaluation of particulate systems supporting tumor cell fractions in a preventive vaccination against intracranial rat glioma. <i>Journal of Neurosurgery</i> , 2006, 105, 745-752.	1.6	3
52	A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1710-1722.	4.1	179
53	Local and Sustained Delivery of 5-Fluorouracil from Biodegradable Microspheres for the Radiosensitization of Malignant Glioma: A Randomized Phase II Trial. <i>Neurosurgery</i> , 2005, 56, 242-248.	1.1	101
54	Drug delivery into the brain using poly(lactide-co-glycolide) microspheres. <i>Expert Opinion on Drug Delivery</i> , 2005, 2, 363-376.	5.0	47

#	ARTICLE	IF	CITATIONS
55	In vitro study of GDNF release from biodegradable PLGA microspheres. <i>Journal of Controlled Release</i> , 2004, 95, 463-475.	9.9	108
56	Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. <i>Journal of Cell Science</i> , 2004, 117, 2971-2981.	2.0	616
57	Influence of 5-Fluorouracil-Loaded Microsphere Formulation on Efficient Rat Glioma Radiosensitization. <i>Pharmaceutical Research</i> , 2004, 21, 1558-1563.	3.5	19
58	Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease. <i>Biomaterials</i> , 2004, 25, 933-942.	11.4	97
59	Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma. <i>Cancer</i> , 2004, 100, 405-410.	4.1	105
60	Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease. <i>Neuroscience Letters</i> , 2004, 356, 207-210.	2.1	44
61	Striatal tyrosine hydroxylase immunoreactive neurons are induced by l-dihydroxyphenylalanine and nerve growth factor treatment in 6-hydroxydopamine lesioned rats. <i>Neuroscience Letters</i> , 2004, 362, 79-82.	2.1	34
62	Therapeutic effectiveness of novel 5-fluorouracil-loaded poly(methylidene malonate 2.1.2)-based microspheres on F98 glioma-bearing rats. <i>Cancer</i> , 2003, 97, 2822-2829.	4.1	42
63	Pseudotumoral demyelination: a diagnosis pitfall (report of three cases). <i>Journal of Neuro-Oncology</i> , 2001, 54, 71-76.	2.9	12
64	Analysis of brain biocompatibility of drug-releasing biodegradable microspheres by scanning and transmission electron microscopy. <i>Journal of Neurosurgery</i> , 2001, 95, 489-494.	1.6	35
65	Intraseptal implantation of NGF-releasing microspheres promote the survival of axotomized cholinergic neurons. <i>Biomaterials</i> , 2000, 21, 2097-2101.	11.4	90
66	Development of microspheres for neurological disorders: From basics to clinical applications. <i>Journal of Controlled Release</i> , 2000, 65, 285-296.	9.9	158
67	Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma. <i>Cancer</i> , 1999, 86, 325-330.	4.1	122
68	NGF release from poly(d,l-lactide-co-glycolide) microspheres. Effect of some formulation parameters on encapsulated NGF stability. <i>Journal of Controlled Release</i> , 1998, 56, 175-187.	9.9	150
69	Effect of Stereotactic Implantation of Biodegradable 5-Fluorouracil-loaded Microspheres in Healthy and C6 Glioma-bearing Rats. <i>Neurosurgery</i> , 1996, 39, 117-124.	1.1	117
70	Drug Targeting into the Central Nervous System by Stereotactic Implantation of Biodegradable Microspheres. <i>Neurosurgery</i> , 1994, 34, 1058-1064.	1.1	56
71	Drug Targeting into the Central Nervous System by Stereotactic Implantation of Biodegradable Microspheres. <i>Neurosurgery</i> , 1994, 34, 1058-1064.	1.1	64